World's Best Scientists 2026 revealed!
Richard L. Schilsky

Richard L. Schilsky

D-Index & Metrics

Medicine

D-Index
102
Citations
64988
World Ranking
7491
National Ranking
3915

Richard L. Schilsky publications per year

1979: 1 publications 1980: 3 publications 1981: 3 publications 1982: 5 publications 1983: 1 publications 1984: 0 publications 1985: 2 publications 1986: 2 publications 1987: 5 publications 1988: 9 publications 1989: 11 publications 1990: 8 publications 1991: 7 publications 1992: 5 publications 1993: 8 publications 1994: 9 publications 1995: 3 publications 1996: 8 publications 1997: 6 publications 1998: 11 publications 1999: 6 publications 2000: 8 publications 2001: 17 publications 2002: 15 publications 2003: 13 publications 2004: 19 publications 2005: 8 publications 2006: 14 publications 2007: 8 publications 2008: 18 publications 2009: 6 publications 2010: 15 publications 2011: 15 publications 2012: 11 publications 2013: 14 publications 2014: 20 publications 2015: 22 publications 2016: 27 publications 2017: 16 publications 2018: 21 publications 2019: 25 publications 2020: 29 publications 2021: 19 publications 2022: 14 publications 2023: 30 publications 2024: 23 publications 2025: 14 publications
1979 2025

554 publications in total across all disciplines

Richard L. Schilsky publication distribution in Medicine in 2027

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2027. The highlighted bar marks where Richard L. Schilsky sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 526 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard L. Schilsky D-index placement in Medicine in 2027

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2027. The highlighted bar marks where Richard L. Schilsky sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard L. Schilsky is affiliated with the University of Chicago in the United States and specializes in medicine, with a significant focus on oncology. Their research contributions span various subfields, including oncology, pulmonary and respiratory medicine, cancer research, economics and econometrics, and molecular biology.

Their primary areas of study include cancer genomics and diagnostics, lung cancer treatments and mutations, colorectal cancer treatments and studies, pancreatic and hepatic oncology research, advanced breast cancer therapies, cancer immunotherapy and biomarkers, and the economic and financial impacts of cancer.

Schilsky has published extensively, with frequent appearances in several prominent publication venues such as:

  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • Cancer Research
  • JCO Oncology Practice
  • UNC Libraries

Recent papers authored or co-authored by Schilsky include:

  • "Closing the Rural Cancer Care Gap: Three Institutional Approaches," 2020, JCO Oncology Practice
  • "Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey," 2020, JCO Oncology Practice
  • "Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study," 2021, Journal of Clinical Oncology
  • "Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology," 2020, Journal of Clinical Oncology
  • "Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement," 2021, Clinical Cancer Research

Frequent collaborators include the following co-authors:

  • Elizabeth Garrett-Mayer
  • Pam K. Mangat
  • Susan Halabi
  • Gina N. Grantham
  • Eugene R. Ahn

Schilsky's scholarly output reflects a multidisciplinary approach to cancer research, integrating clinical oncology with economic and molecular perspectives. Their involvement in studies addressing clinical trial design and cancer care accessibility indicates an engagement with both practical and policy-related dimensions of oncology.

Best Publications

  • AJCC Cancer Staging Manual

    Mahul B. Amin;Stephen B. Edge;Frederick L. Greene;David R. Byrd

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

    Carmen J. Allegra;Carmen J. Allegra;J. Milburn Jessup;Mark R. Somerfield;Stanley R. Hamilton

  • Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

    Jason D. Merker;Geoffrey R. Oxnard;Carolyn Compton;Maximilian Diehn

  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

    Robert S. Sandler;Susan Halabi;John A. Baron;Susan Budinger

  • Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

    Gary M. Strauss;James E. Herndon;Michael A. Maddaus;David W. Johnstone

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

    Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Courtney Tyne

  • Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

    Jeffrey A. Meyerhardt;Denise Heseltine;Donna Niedzwiecki;Donna Hollis

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

    Gary J. Kelloff;John M. Hoffman;Bruce Johnson;Howard I. Scher

  • Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

    Lowell E. Schnipper;Nancy E. Davidson;Dana S. Wollins;Douglas W. Blayney

  • First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

    J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff

  • Recommendations for management of patients with neuroendocrine liver metastases

    Andrea Frilling;Irvin M. Modlin;Mark Kidd;Christopher Russell

  • Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

    G. M. Strauss;J. Herndon;M. A. Maddaus;D. W. Johnstone

  • Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy

    Frederick H. Hausheer;Richard L. Schilsky;Stacey Bain;Elmer J. Berghorn

  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

    Robert S. Sandler;Susan Halabi;John A. Baron;Susan Budinger

  • Cetuximab in the treatment of colorectal cancer.

    Richard M Goldberg;Alan P Venook;Richard L Schilsky

Frequent Co-Authors

Mark J. Ratain
Mark J. Ratain University of Chicago
Donna Niedzwiecki
Donna Niedzwiecki Duke University
Everett E. Vokes
Everett E. Vokes University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Alan P. Venook
Alan P. Venook University of California, San Francisco
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute
Susan Halabi
Susan Halabi Duke University
Richard M. Goldberg
Richard M. Goldberg West Virginia University
Federico Innocenti
Federico Innocenti University of North Carolina at Chapel Hill
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA opens many doors beyond the traditional MD pathway. For those interested in patient care, online nurse practitioner programs provide the flexibility to advance your education and clinical skills while working. These programs are ideal for registered nurses seeking greater autonomy and specialized roles.

Cost is a major factor for many students. Thankfully, the cheapest online MSN programs make advanced nursing degrees more accessible. These affordable options allow nurses to pursue leadership, teaching, or advanced practice roles without incurring overwhelming debt.

For those aiming for academic or research-oriented careers, a phd in nursing unlocks opportunities in university teaching, research, and specialized clinical practice. Online formats make it possible to balance these rigorous programs with work and family life.

If you are a registered nurse looking to boost your credentials and earning potential, consider the cheapest rn to bsn online programs. Completing a BSN can lead to better job opportunities, higher salaries, and a solid foundation for further study in the medical field.

Best Scientists Citing Richard L. Schilsky

Trending Scientists

Recently Published Articles